Evidence map›Paper›PMID 26839021›Full record

ReviewFuture oncology (London, England)2016

The evolving role of enzalutamide on the treatment of prostate cancer.

Rosa Nadal, Joaquim Bellmunt

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Future oncology (London, England), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Rosa NadalCenter for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA.
Joaquim BellmuntDana-Farber Cancer Institute & Harvard Medical School, Boston, MA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The field of prostate cancer has witnessed incredible progress in the last decade, owing to the approval of multiple survival-prolonging treatments for metastatic castration-resistant prostate cancer (mCRPC). Enzalutamide is a nonsteroidal androgen receptor inhibitor that targets multiple steps in the androgen receptor signaling axis. It has been approved for the treatment of mCRPC both in the postdocetaxel and in the chemotherapy-naive settings. We summarize the milestones in the development of enzalutamide in patients with prostate cancer. Special focus is placed on the results of the STRIVE Phase II clinical trial comparing head to head enzalutamide and bicalutamide in patients with nonmetastatic and mCRPC who have failed androgen deprivation and in other ongoing trials in the same setting and in earlier disease phases.

Indexed as

Androgen Receptor AntagonistsAnimalsAntineoplastic AgentsAntineoplastic Agents, HormonalBenzamidesClinical Trials as TopicDrug Evaluation, PreclinicalDrug Resistance, NeoplasmHumansMaleNeoplasm MetastasisNitrilesPhenylthiohydantoinProstatic NeoplasmsProstatic Neoplasms, Castration-ResistantReceptors, AndrogenAndrogen Receptor AntagonistsAntineoplastic AgentsAntineoplastic Agents, HormonalBenzamidesenzalutamideNitrilesPhenylthiohydantoinReceptors, Androgencastration-resistant prostate cancerenzalutamidehormone-sensitive prostate cancerprostate cancerSTRIVE

Identifiers

PMID26839021
PMCPMC5551941

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.